vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
Globe Newswire•27/10/2026•08:00 ET
0
Key Highlights
- ➤First participant randomized in Phase 2a Hybrid CATT1 pilot study
- ➤Study expected to enroll approximately 40 adults with T1D using HCL systems
- ➤Primary endpoint evaluates six-week cadisegliatin effects on CGM-based Time in Range
- ➤Phase 3 CATT1 enrollment completed earlier this month using open-loop insulin delivery
- ➤Cadisegliatin holds FDA Breakthrough Therapy designation as a potential T1D adjunct
Expert Statements
Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics
“Although HCL systems have improved the lives of people living with T1D, the risk and associated fear of hypoglycemia remain a significant burden on their day-to-day lives”
Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics
“As we advance our cadisegliatin program, this study seeks to deepen our understanding of how cadisegliatin may help improve glycemic control and reduce the burden of hypoglycemia for people who use HCL insulin delivery systems.”
Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population
Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the treatment of T1D
Get started
Create a free account to read the full story.